ResearcherHeidelberg UniversityNo recent work listed
Friedrich Hubertus Schmitz-Winnenthal
Matched on OpenAlex author ID A5110475611. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper
Papers 4
- A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients w… Co-author DOI 10.1080/2162402x.2017.1303584↗
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
- Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for… Co-author DOI 10.1186/1471-2407-14-168↗
- Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients… Last author DOI 10.1186/1471-2407-12-361↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Philipp Beckhove · 4 shared papers, 2012–2018 · strength 0.17
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Tr… DOI 10.1186/1471-2407-14-168↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Thomas Schmidt · 3 shared papers, 2014–2018 · strength 0.14
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Tr… DOI 10.1186/1471-2407-14-168↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Markus Wolfgang Büchler · 3 shared papers, 2012–2018 · strength 0.13
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Tr… DOI 10.1186/1471-2407-14-168↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Nicolas Hohmann · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Lars Grenacher · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Christoph Springfeld · 2 shared papers, 2015–2018 · strength 0.10
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Andreas G. Niethammer · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Jürgen Weitz · 2 shared papers, 2012–2015 · strength 0.06
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Frank Pianka · 1 shared paper, 2015 · strength 0.03
- Ulla Klaiber · 1 shared paper, 2015 · strength 0.03
- Markus K. Diener · 1 shared paper, 2015 · strength 0.03
- Alexis B. Ulrich · 1 shared paper, 2015 · strength 0.03
- Moritz Koch · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.